市场调查报告书
商品编码
1403333
全球太空基因组学和转录组学市场:按类型、技术、应用、产品和最终用户 - 预测(~2031 年)Spatial Genomics Market by Type (Genomics, Transcriptomics) Technology (Sequencing, Imaging) Application (Oncology, Neurology) Offering (Consumables, Instrument, Software) End User (Pharmaceutical & Biotechnology, CRO) - Global Forecast to 2031 |
至2031年,全球太空基因组学和转录组学市场规模预计将达到32.3亿美元,2024年至2031年复合年增长率为27.8%。
该报告在广泛的二级和一级研究以及对市场情景的深入分析后,对关键行业驱动因素、限制因素、挑战和机会进行了分析。空间基因组学市场的成长是由空间基因组学在药物发现研究和开发中的使用扩展、空间基因组学在癌症研究中的使用扩展、下一代测序(NGS)的进步、空间基因组学的扩展、空间基因组学在生物标记检测和癌症研究中的应用。这是由于以下疾病盛行率的增加所驱动的然而,基因组学缺乏标准化方法以及对基因组资料安全和隐私的担忧正在限制该市场的成长。
此外,个人化药物和基因疗法的日益普及,以及空间基因组学投资的增加,预计将为在该市场运营的公司提供成长机会。然而,数据分析的复杂性和技术实施缓慢是影响市场成长的主要挑战。
该报告基于对多年来(2020-2024 年)领先产业参与者所采用的产品组合、区域发展和关键策略发展的广泛评估,提供了竞争格局。全球太空基因组学和转录组学市场的主要公司包括 NanoString Technologies, Inc.(美国)、10X Genomics, Inc.(美国)、Illumina, Inc.(美国)、Oxford Nanopore Technologies Plc(英国)、Akoya Biosciences、 Inc.(美国)、Revvity, Inc.(美国)、S2 Genomics, Inc.(美国)、Cantata Bio(美国)、Vizgen Inc.(美国)、Biospyder Technologies Inc.(美国)。)、Resolve Biosciences GmbH(德国)
在本报告研究的所有产品中,设备领域预计在预测期内复合年增长率最高。学术和研究机构采用空间转录组学进行肿瘤微环境分析、药物发现和转化研究,对空间基因组学设备的需求产生了积极影响。此外,主要市场参与者推出的产品正在支持市场成长。例如,2022年12月,10X Genomics, Inc.(美国)推出了用于细胞内原位分析的Xenium分析仪。
在本报告研究的所有类型中,转录组学领域预计将在 2024 年占据空间基因组学和转录组学市场的最大份额。此细分市场的最大份额归因于空间转录组学的日益使用,以提供转化研究所需的整个组织切片内转录活性的完整路线图。此外,用于识别细胞成分的空间转录组学技术的日益接受也推动了市场的成长。
在本报告调查的所有技术中,基于序列的细分市场预计在预测期内复合年增长率最高。该领域的成长归因于NGS平台以显着降低的成本提供卓越的定序能力,从而增加了NGS在产生大量基因组定序数据的基因组研究中的使用。此外,高通量、低成本、单一细胞表征和多个目标的分析正在推动市场成长。
在本报告调查的所有应用中,预计到 2024 年,肿瘤学将占据空间基因组学和转录组学市场的最大份额。空间基因组学和转录组学在肿瘤生物学中的应用不断增加,例如研究肿瘤异质性、检测浸润免疫细胞的存在以及洞察肿瘤微环境,为这一领域带来了最大的份额。此外,主要市场参与者推出的产品占了最大的份额。例如,2023 年 4 月,Akoya Biosciences(美国)推出了 PhenoCode Discovery Panel,以推进癌症研究。
在本报告研究的所有最终用户中,製药和生技公司领域预计在预测期内将以最高的复合年增长率成长。这一增长的推动因素包括製药和生物技术公司研发的增加、研究方法中空间基因组学分析的使用增加以及生物技术公司的增加。此外,慢性病的增加加速了加快药物开发进程的需求,进一步推动了製药公司采用空间基因组学。
对全球空间基因组学和转录组学市场区域状况的详细分析为五个关键区域(北美、欧洲、亚太地区、拉丁美洲、中东和非洲)提供了详细的定性和定量见解,涵盖了主要国家。到 2024 年,北美预计将占据空间基因组学和转录组学市场的最大份额。北美在该地区占据主导地位,这主要是因为其拥有大量从事基因组学研究的受人尊敬的研究机构、大学和组织。由于对药物研发的大量投资以及主要行业参与者的存在,该地区在癌症基因组学的发展中发挥关键作用。例如,加拿大製药公司用于药物发现的研发支出不断增加,推动了对空间基因组学的需求。例如,2020 年加拿大製药业的研发总支出预计在 18 亿美元至 24 亿美元之间,而 2019 年为 16 亿美元至 22 亿美元。
(註:包含前5名企业的SWOT分析)
Spatial Genomics Market by Type (Genomics, Transcriptomics) Technology (Sequencing, Imaging) Application (Oncology, Neurology) Offering (Consumables, Instrument, Software) End User (Pharmaceutical & Biotechnology, CRO)-Global Forecast to 2031
The global spatial genomics & transcriptomics market is expected to reach $3.23 billion by 2031 at a CAGR of 27.8% from 2024 to 2031.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the spatial genomics market is driven by the increasing applications of spatial genomics in drug discovery & development, the growing use of spatial genomics in cancer research, advancements in Next-generation Sequencing (NGS), the increasing use of spatial genomics in biomarker detection, and the rising prevalence of cancer. However, the lack of standardized approaches in genomics and concerns over the security & privacy of genomic data restrain the growth of this market.
Furthermore, the rising adoption of personalized medicines and gene therapies and increasing investments in spatial genomics are expected to generate growth opportunities for the players operating in this market. However, complexities in data analysis and slow technology adoption are major challenges impacting market growth.
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over the years (2020-2024). The key players operating in the global spatial genomics & transcriptomics market are NanoString Technologies, Inc. (U.S.), 10X Genomics, Inc. (U.S.), Illumina, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), Akoya Biosciences, Inc. (U.S.), Revvity, Inc. (U.S.), S2 Genomics, Inc. (U.S.), Cantata Bio (U.S.), Vizgen Inc. (U.S.), Biospyder Technologies Inc. (U.S.), and Resolve Biosciences GmbH (Germany).
Among all the offerings studied in this report, the instruments segment is projected to register the highest CAGR during the forecast period. The use of instruments to profile the tumor microenvironment and the adoption of spatial transcriptomics in academics and research laboratories for drug and translational research are positively impacting the demand for instruments used in spatial genomics. Additionally, product launches by key market players support market growth. For instance, in December 2022, 10X Genomics, Inc. (U.S.) launched a Xenium Analyzer for subcellular in situ profiling.
Among all the types studied in this report, in 2024, the transcriptomics segment is expected to account for the largest share of the spatial genomics & transcriptomics market. The largest share of the segment is attributed to the increasing use of spatial transcriptomics to provide a complete roadmap of transcriptional activity within whole tissue sections required in translational research. Additionally, increasing acceptance of spatial transcriptomic technology for the identification of cellular components is driving the market growth.
Among all the technologies studied in this report, the sequencing-based segment is projected to register the highest CAGR during the forecast period. The growth of the segment is attributed to the NGS platforms offering superior sequencing capacity at substantially reduced costs, owing to which the use of NGS has increased in genomic studies to produce massive genomic sequencing data. Additionally, high throughput, low cost, individual characterization of cells, and analysis of multiple targets drive the market growth.
Among all the applications studied in this report, in 2024, the oncology segment is expected to account for the largest share of the spatial genomics & transcriptomics market. Increasing applications of spatial genomics & transcriptomics in tumor biology, such as the study of tumor heterogeneity, detecting the presence of infiltrating immune cells, and insights into tumor microenvironment, are contributing to the largest share of the segment. Additionally, the product launches by key market players are supporting the largest market share. For instance, in April 2023, Akoya Biosciences (U.S.) launched PhenoCode Discovery Panels for the advancements in cancer research.
Among all the end users studied in this report, the pharmaceutical & biotechnology companies segment is expected to grow at the highest CAGR during the forecast period. The growth is attributed to the increasing research & development by pharmaceutical & biotechnology companies, the rising utilization of spatial genomics assays for research processes, and an increasing number of biotechnology companies. Moreover, the rising incidence of chronic diseases has accelerated the need to expedite drug development processes, further propelling the adoption of spatial genomics among pharmaceutical companies.
An in-depth analysis of the geographical scenario of the global spatial genomics & transcriptomics market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of the spatial genomics & transcriptomics market. North America holds the predominant share in the region, largely due to its multitude of esteemed research institutions, universities, and organizations committed to genomics research. The region has played a pivotal role in advancing cancer genomics, driven by substantial investments in pharmaceutical research and development and the significant presence of key industry players. For instance, R&D spending by pharmaceutical companies in Canada for drug discovery has increased, driving the demand for spatial genomics. For instance, in 2020, total R&D expenditure in Canada's pharmaceutical sector was estimated at between USD 1.8 billion and USD 2.4 billion, compared to USD 1.6 billion and USD 2.2 billion in 2019
Spatial Genomics Market Assessment, by Offering
Spatial Genomics Market Assessment, by Type
Spatial Genomics Market Assessment, by Technology
Spatial Genomics Market Assessment, by Application
Note: Other applications consist of infectious diseases and immunology.
Spatial Genomics Market Assessment, by End User
Note: Other end users include academic institutes & research centers and agriculture companies.
Spatial Genomics Market Assessment, by Geography
(Note: SWOT Analysis of Top 5 Companies is Provided)